Angiomax Gains Second Label Expansion For 2005
Supplement cleared Nov. 30 allows use of the anticoagulant bivalirudin in percutaneous coronary intervention patients at risk for heparin-induced thrombocytopenia or thrombosis syndrome.
Supplement cleared Nov. 30 allows use of the anticoagulant bivalirudin in percutaneous coronary intervention patients at risk for heparin-induced thrombocytopenia or thrombosis syndrome.